Abstract
Hyaluronan receptors (CD44, RHAMM) are over-expressed in a wide variety of cancers including bladder and ovarian tumors. Based on this rationale, a hyaluronic acid paclitaxel conjugate, ONCOFID™-P, was developed for the treatment of refractory bladder cancer and peritoneal carcinosis. ONCOFID™-P has demonstrated improved in vitro and in vivo efficacy in hyaluronan receptor-positive tumor models and a favorable toxicity profile in rodents. It has been investigated in 15 patients with refractory bladder cancer by intravesical instillation, showing promising antitumor efficacy with 60 % of treated patients achieving a complete response. As a consequence, phase II studies with ONCOFID™-P are ongoing in six European countries. In addition, phase I studies have been initiated investigating the maximum tolerated dose (MTD) and the safety profile of ONCOFID™-P following IP infusion in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder and colon cancer.
Keywords: Hyaluronic acid, paclitaxel, anticancer, conjugate, bladder cancer, peritoneal carcinosis, colon cancer, antitumor, polysaccharide, drug conjugate
Current Bioactive Compounds
Title: ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis
Volume: 7 Issue: 1
Author(s): Monica Campisi and Davide Renier
Affiliation:
Keywords: Hyaluronic acid, paclitaxel, anticancer, conjugate, bladder cancer, peritoneal carcinosis, colon cancer, antitumor, polysaccharide, drug conjugate
Abstract: Hyaluronan receptors (CD44, RHAMM) are over-expressed in a wide variety of cancers including bladder and ovarian tumors. Based on this rationale, a hyaluronic acid paclitaxel conjugate, ONCOFID™-P, was developed for the treatment of refractory bladder cancer and peritoneal carcinosis. ONCOFID™-P has demonstrated improved in vitro and in vivo efficacy in hyaluronan receptor-positive tumor models and a favorable toxicity profile in rodents. It has been investigated in 15 patients with refractory bladder cancer by intravesical instillation, showing promising antitumor efficacy with 60 % of treated patients achieving a complete response. As a consequence, phase II studies with ONCOFID™-P are ongoing in six European countries. In addition, phase I studies have been initiated investigating the maximum tolerated dose (MTD) and the safety profile of ONCOFID™-P following IP infusion in patients affected by intraperitoneal carcinosis in ovarian, breast, stomach, bladder and colon cancer.
Export Options
About this article
Cite this article as:
Campisi Monica and Renier Davide, ONCOFID™-P a Hyaluronic Acid Paclitaxel Conjugate for the Treatment of Refractory Bladder Cancer and Peritoneal Carcinosis, Current Bioactive Compounds 2011; 7 (1) . https://dx.doi.org/10.2174/157340711795163848
DOI https://dx.doi.org/10.2174/157340711795163848 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Recent Advances in Chalcone-Based Anticancer Heterocycles: A Structural and Molecular Target Perspective
Current Medicinal Chemistry A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32.
Drug Metabolism Letters The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents 3,7-Bis(dialkylamino)phenothiazin-5-ium Derivatives: Biomedical Applications and Biological Activity
Current Drug Targets The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety Recent Advance in the Research of Flavonoids as Anticancer Agents
Mini-Reviews in Medicinal Chemistry OX40 and OX40L Interaction in Cancer
Current Medicinal Chemistry Screening of Drug Efficacy of Rosmarinic Acid Derivatives as Aurora Kinase Inhibitors by Computer-Aided Drug Design Method
Current Computer-Aided Drug Design Urinary Tract Tumors, Biology and Risk for Artificial Sweeteners Use with Particular Emphasis on some South American Countries
Current Nutrition & Food Science The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Non-aspirin Non-steroidal Anti-inflammatory Drugs for the Primary Chemoprevention of Non-gastrointestinal Cancer: Summary of Evidence
Current Pharmaceutical Design Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Insight into Pain Modulation: Nociceptors Sensitization and Therapeutic Targets
Current Drug Targets